Re: [GRG] Possible vaccine for heart disease in development

thanks very much for this abstract!


On Wed, Jul 16, 2014 at 6:23 PM, wrote:
Contact: Julie O’
Wayne State University – Office of the Vice President for Research
Fundamental research is paving the way for development of first
vaccine for heart disease
DETROIT — Researchers at Wayne State University have made a
fundamental discovery and, in subsequent collaboration with
scientists at La Jolla Institute for Allergy and Immunology (LIAI),
are one step closer to the goal of developing the world’s first T-
cell peptide-based vaccine for heart disease — the number one
killer in the nation.
Atherosclerosis is a chronic inflammatory disease of the arterial
walls, which thicken due to accumulation of fatty materials such as
cholesterols and triglycerides. Blocking of arteries supplying
blood to the heart is the underlying cause of many heart diseases.
Nearly 600,000 Americans die of heart disease every year. Although
cholesterol is believed to be a major factor in creating the plaque
that leads to heart disease, immune inflammation is another
important contributor in arterial plaque buildup. The goal of the
vaccine is to reduce immune-based inflammation in the arteries,
leading to decreased plaque buildup.
The scientists published their findings in the December 2013 issue
of Frontiers in Immunology, entitled “Atheroprotective vaccination
with MHC-II restricted peptides from ApoB-100.” These experiments
show proof of concept for the development of an autoantigen-
specific vaccine for reducing the amount of atherosclerotic plaques
in mice. If successful, the vaccine could aid in preventing heart
disease and stop or reduce disease progression. In addition to
heart disease, the vaccine could target strokes, which are also a
product of plaque buildup in arteries.
The published work, performed in the laboratory of Klaus Ley, M.D.,
a prominent vascular biologist of LIAI, was based on the
fundamental discovery made by Harley Tse, Ph.D., professor of
immunology and microbiology in Wayne State’s School of Medicine,
and professor in Wayne State’s Cardiovascular Research Institute,
and Michael Shaw, Ph.D., adjunct assistant professor of immunology
and microbiology at Wayne State. Shaw and Tse are the first to
demonstrate that two T cell epitopes of the autoantigen apoB100 are
deeply involved in the development of the disease. Their novel
discovery is reported in the article, “Identification of two
Immunogenic T cell Epitopes of ApoB-100 and their Autoimmune
Implications,” published in the April – June 2014 issue (volume 2)
of Journal of Immunology and Clinical Research.
“ApoB100 is an apolipoprotein of the LDL (low-density lipoprotein)
particle which is the notorious ‘bad cholesterol’ that contributes
to the formation of plaques in the vessel wall,” said Tse.
“Although T cells of the immune system are known to participate in
the development of heart disease, by what and how these T cells are
directed to act have not been elucidated. The lack of this
knowledge has greatly hampered the development of immune peptide-
based therapeutics to control the disease. With the discovery of
the disease-causing T cell epitopes, we can now manipulate the
activities of the T cells responding to these epitopes to control
the disease.”
Since immune T cells are normally activated by a short sequence
(called an epitope), and not by the whole molecule of an antigen,
Shaw and Tse conceptualized that finding the apoB100 epitopes
capable of stimulating the disease causing (atherogenic) T cells is
a prerequisite for understanding how these T cells are involved in
heart disease development and for finding ways to control their
adverse effects.
Based on this idea, they identified two short sequences (3501–3515
and 978–992) of ApoB100 (ApoB3501-3515 and ApoB978-992, also
designated peptides P3 and P6, respectively) that were able to
direct specific T cells to proliferate as well as to cause
worsening atherosclerosis. This discovery is significant because it
identifies the target T cells and makes it possible to manipulate
this population of pathologic T cells away from their harmful
The subsequent collaboration with Ley’s laboratory bears the first
fruits of this effort.


About Johnny Adams

My full-time commitment is to slow and ultimately reverse age related functional decline to increase healthy years of life. I’ve been active in this area since the 1970s, steadily building skills and accomplishments. I have a good basic understanding of the science of aging, and have many skills that complement those of scientists so they can focus on science to advance our shared mission. Broad experience Top skills: administration, management, information technology (data and programming), communications, writing, marketing, market research and analysis, public speaking, forging ethical win-win outcomes among stakeholders (i.e. high level "selling"). Knowledge in grant writing, fundraising, finance. Like most skilled professionals, I’m best described as a guy who defines an end point, then figures out how to get there. I enjoy the conception, design, execution and successful completion of a grand plan. Executive Director Gerontology Research Group (GRG). Manages Email discussion forum, web site, meetings and oversees supercentenarian (oldest humans, 110+ years) research. CEO / Executive Director Carl I. Bourhenne Medical Research Foundation (Aging Intervention Foundation), an IRS approved 501(c)(3) nonprofit. Early contributor to Supercentenarian Research Foundation. Co-Founder Geroscience Healthspan Forum. Active contributor to numerous initiatives to increase healthy years of life. Co-authored book on conventional, practical methods available today to slow the processes of aging – nutrition, exercise, behavior modification and motivation, stress reduction, proper supplementation, damage caused by improper programs, risk reduction and others. Fundamental understanding of, and experience in the genomics of longevity (internship analyzing and curating longevity gene papers). Biological and technical includes information technology, software development and computer programming, bioinformatics and protein informatics, online education, training programs, regulatory, clinical trials software, medical devices (CAT scanners and related), hospital electrical equipment testing program. Interpersonal skills – good communication, honest, well liked, works well in teams or alone. Real world experience collaborating in interdisciplinary teams in fast paced organizations. Uses technology to advance our shared mission. Education: MBA 1985 University of Southern California -- Deans List, Albert Quon Community Service Award (for volunteering with the American Longevity Association and helping an elderly lady every other week), George S. May Scholarship, CA State Fellowship. BA psychology, psychobiology emphasis 1983 California State University Fullerton Physiological courses as well as core courses (developmental, abnormal etc). UCLA Psychobiology 1978, one brief but fast moving and fulfilling quarter. Main interest was the electrochemical basis of consciousness. Also seminars at the NeuroPsychiatric Institute. Other: Ongoing conferences, meetings and continuing education. Aging, computer software and information technology. Some molecular biology, biotech, bio and protein informatics, computer aided drug design, clinical medical devices, electronics, HIPAA, fundraising through the Assoc. of Fundraising Professionals. Previous careers include: Marketing Increasing skill set and successes in virtually all phases, with valuable experience in locating people and companies with the greatest need and interest in a product or service, and sitting across the table with decision makers and working out agreements favorable to all. Information Technology: Management, data analysis and programming in commercial and clinical trials systems, and bioinformatics and protein informatics. As IT Director at Newport Beach, CA based technology organization Success Family of Continuing Education Companies, provided online software solutions for insurance and financial professionals in small to Fortune 500 size companies. We were successful with lean team organization (the slower moving competition was unable to create similar software systems). Medical devices: At Omnimedical in Paramount CA developed and managed quality assurance dept. and training depts. for engineers, physicians and technicians. Designed hospital equipment testing program for hospital services division. In my early 20’s I was a musician, and studied psychology and music. Interned with the intention of becoming a music therapist. These experiences helped develop valuable skills used today to advance our shared mission of creating aging solutions.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s